Biolevate Raises €30M Series A and Opens Boston Office for Its Life Sciences AI
September 22, 2026 - 9:08 am
Biolevate’s founders, including co-founder and CEO Joël Belafa.
The Paris-based company Biolevate, which develops AI automation for use in regulated life sciences, has raised €30m in its Series A funding and opened an office in Boston. Orange Ventures and RAISE France co-led the fundraising exercise, with the latter being the investment arm of Aymar Hénin, a French entrepreneur.
The MSD Global Health Innovation Fund, Station F, and existing investor EQT Ventures also participated. EQT led Biolevate’s €6m seed round in November 2024, when the startup was focused on medical writing.
Founded by former Dataiku engineers and AI researchers, the company initially aimed to speed up the process of obtaining regulatory approval. Its agentic platform converts scientific and regulatory knowledge into auditable workflows, linking each output to the evidence supporting it—still requiring a person to sign off.
The platform covers the entire process from early research and drug discovery through clinical trials, regulatory submissions, and health technology assessments. Biolevate claims its platform can run 100,000 agents at a time, conducts literature reviews and evidence synthesis 16 times faster, and makes regulatory intelligence 80% more efficient.
Over 12 enterprise customers currently use the platform in production, with the company's annual recurring revenue increasing 20-fold over the last year. Notable partners include Sanofi, regulators, NVIDIA, and Microsoft. The team has grown to 50 members, with plans to double that number next year.
The Boston office establishes the company’s presence at the heart of the US pharmaceutical industry as it expands overseas.
Under the terms of the agreement, Hénin is appointed chairman of the board, and Jérôme Berger, head of group strategy and venture capital at Orange, joins the board.
Joël Belafa, Biolevate’s co-founder and CEO, stated:
“We started Biolevate with a mission-driven team united by the belief that AI could improve millions of lives if we empowered the right people and solved the right technological challenges.”
Hénin added:
“Biolevate is transforming AI’s potential into automation that people can trust at scale in regulated environments.”